GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (FRA:8EM) » Definitions » Dividend-Payout-to-FFO

Editas Medicine (FRA:8EM) Dividend-Payout-to-FFO


View and export this data going back to 2016. Start your Free Trial

What is Editas Medicine Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.


Editas Medicine Business Description

Traded in Other Exchanges
Address
11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.